Abstract
BackgroundAlthough anti-HER2 monoclonal antibodies (e.g., trastuzumab) are currently recognized as effective therapeutics in patients with HER2-overexpressing tumors, a significant number of patients demonstrate resistance to this treatment. Genetic modification of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
